Welcome to our dedicated page for The Beauty Health Company SEC filings (Ticker: SKIN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beauty Health Company (NASDAQ: SKIN) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a medtech meets beauty business in skin health and aesthetics. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Investors can use this resource to access current reports on Form 8-K, where BeautyHealth discloses material events such as quarterly financial results, leadership transitions, board appointments, debt and indenture changes, and amendments to its certificate of incorporation. For example, recent 8-K filings discuss the appointment of a new President and Chief Executive Officer, the appointment of a new independent director, a supplemental indenture related to 7.95% convertible senior notes due 2028, and a certificate of correction to its charter.
In addition to 8-Ks, the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) provide detail on net sales, gross margin, adjusted EBITDA, delivery systems sold, active install base, regional performance, risk factors, and capital structure. These filings outline how BeautyHealth combines delivery systems and consumables in its revenue model and how it reports non-GAAP measures alongside GAAP results.
This page also offers easy access to insider and equity-related filings, such as Forms 3, 4, and 5 when they are filed, which can show transactions by directors and officers, as well as proxy and governance documents that describe director compensation, board structure, and key agreements. AI-generated explanations help clarify complex sections, highlight important changes, and point out items that may matter most to shareholders, analysts, and anyone researching SKIN’s regulatory history.
Malha Pedro Bruno Ferreira reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that President and CEO Pedro Bruno Ferreira Malha received a grant of 2,654,867 restricted stock units (RSUs) of Class A Common Stock as equity compensation. Each RSU represents one share of stock and vests in three equal annual installments starting on the first anniversary of the March 20, 2026 grant date, subject to continued service and certain acceleration rights.
After this award, Malha is shown as beneficially owning 4,845,251 shares of Class A Common Stock directly. The transaction was recorded at a price of $0.00 per share, reflecting that it is a compensation grant rather than an open-market purchase.
MONAHAN MICHAEL P. reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that Chief Financial Officer Michael P. Monahan received a grant of 746,681 restricted stock units of Class A Common Stock. These RSUs vest in three equal annual installments starting on March 20, 2026, contingent on continued service and certain acceleration provisions. Following this award, Monahan directly holds 2,014,413 shares or share-equivalent units, reflecting a compensation-related equity grant rather than an open-market transaction.
Menezes Ronald reported acquisition or exercise transactions in this Form 4 filing.
Beauty Health Co reported that Chief Revenue Officer Ronald Menezes received a large equity grant in the form of restricted stock units (RSUs). He was awarded 746,681 RSUs of Class A Common Stock at no purchase price as part of his compensation.
Each RSU represents a future right to receive one share of Class A Common Stock, subject to time-based vesting. The award vests in three equal installments on each of the first three anniversaries of the March 20, 2026 grant date, contingent on continued service and certain acceleration rights. Following this grant, Menezes directly owns 1,759,915 shares of the company’s Class A Common Stock.
Beauty Health Co reported that CSO and COO Sheri Lewis received an equity compensation grant of 746,681 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents a contingent right to receive one share, subject to time-based vesting and continued service conditions.
The RSUs vest in three equal installments on each of the first three anniversaries of the March 20, 2026 grant date, with certain acceleration rights. Following this grant, Lewis beneficially owns 1,609,524 shares of Class A Common Stock directly, reflecting a large, compensation-related, non-market acquisition rather than an open-market purchase.
Beauty Health Co executive Sheri Lewis reported a routine tax-related share disposition. On March 17, she had 51,883 shares of Class A common stock withheld by the company at $1.17 per share to cover tax obligations on vesting restricted stock units. The footnote clarifies this was not an open-market sale, and she still directly holds 862,843 shares after the transaction.
Beauty Health Co Chief Revenue Officer reports tax share withholding. Ronald Menezes had 61,471 shares of Class A Common Stock withheld at $1.17 per share on March 17, 2026 to cover taxes on vesting restricted stock units. After this non-sale disposition, he directly holds 1,013,234 shares.
Beauty Health Co Chief Financial Officer Michael P. Monahan reported a tax-related share disposition tied to vesting of restricted stock units. The filing shows 58,573 shares of Class A Common Stock valued at $1.17 per share were withheld by the company to satisfy tax withholding requirements and explicitly notes this does not represent a sale in the market. After this withholding, Monahan directly holds 1,267,732 shares of Class A Common Stock, indicating he retains a substantial equity position following the RSU vesting event.
The Beauty Health Company files its annual report describing a global medical aesthetics business built around Hydrafacial devices and recurring consumables. The company uses a razor/razor-blade model, selling Delivery Systems and single-use tips, solutions and serums to providers such as dermatologists and medical spas.
About 69% of U.S. and Canadian sales come from the professional medical channel, and approximately 35% of 2025 net sales were generated outside the United States and Canada. Beauty Health reports aided Hydrafacial brand awareness of 38% among U.S. esthetics consumers and estimates roughly 60% U.S. market share in the microdermabrasion category.
The report details a growth strategy focused on salesforce discipline, demand-driving marketing, and clinically supported innovation, including SkinStylus microneedling and a potential HydraScalp relaunch. It also highlights extensive risk factors, patent protection with 226 granted patents and 84 pending applications, moderate seasonality with stronger fourth-quarter results, and heavy U.S. and international regulatory oversight of its devices and cosmetic products.
The Beauty Health Company reported mixed 2025 results, with lower sales but much stronger profitability. Net sales were $300.8M, down 10.0% from 2024, as delivery system sales fell even though consumables held up.
Gross margin improved sharply to 65.3% from 54.5%, helped by fewer inventory charges and a richer mix of consumables. Net loss narrowed to $9.5M from $29.1M, and adjusted EBITDA increased to $45.1M from $12.3M, reflecting lower operating expenses and better margins. Cash, cash equivalents, and restricted cash were $232.7M at December 31, 2025, while convertible senior notes declined to $364.4M in total. For 2026, the company guides net sales of $285–$305M and adjusted EBITDA of $35–$45M, implying relatively stable revenue with continued focus on profitability.
The Beauty Health Company filed an 8-K to notify stockholders about a proposed settlement of a consolidated stockholder derivative action in Delaware Chancery Court. The settlement is a non-monetary resolution focused on corporate governance reforms and does not include any cash distribution to stockholders.
The company agreed to measures such as a Quality Ombudsman role, enhanced inventory and returns monitoring, stronger oversight of public financial projections, an expanded clawback policy, and formalized disclosure and product committees. Plaintiffs’ counsel negotiated a proposed fee and expense award of $737,500, to be paid by Beauty Health and/or its insurers, subject to court approval at a settlement hearing on May 13, 2026.